Wu Wei, Yang Xueqin, Kou Ling
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Cardiovasc Diagn Ther. 2025 Aug 30;15(4):847-860. doi: 10.21037/cdt-2025-290. Epub 2025 Aug 28.
The safety of administering vasopressors through peripheral venous catheters (PVCs) remains controversial, primarily due to concerns regarding extravasation, thrombosis, and catheter-related infections. This study aimed to systematically summarize the prevalence of these complications through a meta-analysis.
The PubMed, Excerpta Medical Database (Embase), Cochrane Library, Web of Science (WOS), China National Knowledge Infrastructure (CNKI), Wanfang (WF), Chinese Science and Technology Journal Database (VIP), and China Biology Medicine disc (CBMdisc) databases were systematically searched (from database establishment 16 August 2025) to retrieve pertinent articles, and study quality was rated via the Joanna Briggs Institute (JBI) scale and Newcastle-Ottawa Scale (NOS). The data analysis was conducted using the meta package in R, and random/fixed-effects models were applied to combine the complication rates based on heterogeneity. Sensitivity and subgroup analyses were also carried out.
A total of 19 studies comprising 6,852 patients across 10 counties, including Sweden, the USA, and China, were encompassed in the meta-analysis, with the majority being intensive care unit (ICU) patients. The overall rates of extravasation, thrombosis, and infection were 1.43% [95% confidence interval (CI): 0.72-2.32%; I=71%], 1.47% (95% CI: 0.32-3.18%; I=86%), and 0.72% (95% CI: 0.14-1.60%; I=63%), respectively. The subgroup analysis peripherally inserted central catheters (PICCs) carried a higher risk of thrombosis, while midline catheters (MCs) had the lowest risk of extravasation. In relation to the catheter-related infection risks, PVCs showed the lowest incidence, whereas PICCs had the highest. Limited direct comparative evidence indicated no statistically significant differences between PVCs and central venous catheters (CVCs).
Under standardized procedures, PVCs may be a viable option for vasopressor infusion, particularly MCs, which showed the lowest risk of extravasation. Caution is warranted with PICCs due to the potential risk of thrombosis, while traditional PVCs should be limited to short-term or emergency use. Future well-designed studies with standardized definitions are needed to strengthen the reliability and clinical applicability of the evidence.
通过外周静脉导管(PVC)给予血管升压药的安全性仍存在争议,主要是因为担心外渗、血栓形成和导管相关感染。本研究旨在通过荟萃分析系统总结这些并发症的发生率。
系统检索了PubMed、医学文摘数据库(Embase)、Cochrane图书馆、科学引文索引(WOS)、中国知网(CNKI)、万方(WF)、维普中文科技期刊数据库(VIP)和中国生物医学文献数据库(CBMdisc)(从数据库建立至2025年8月16日)以检索相关文章,并通过乔安娜·布里格斯研究所(JBI)量表和纽卡斯尔-渥太华量表(NOS)对研究质量进行评分。使用R语言中的meta包进行数据分析,并应用随机/固定效应模型根据异质性合并并发症发生率。还进行了敏感性和亚组分析。
荟萃分析共纳入了来自瑞典、美国和中国等10个国家的19项研究,涉及6852例患者,其中大多数为重症监护病房(ICU)患者。外渗、血栓形成和感染的总体发生率分别为1.43% [95%置信区间(CI):0.72 - 2.32%;I² = 71%]、1.47%(95% CI:0.32 - 3.18%;I² = 86%)和0.72%(95% CI:0.14 - 1.60%;I² = 63%)。亚组分析显示,外周中心静脉导管(PICC)发生血栓形成的风险较高,而中线导管(MC)发生外渗的风险最低。关于导管相关感染风险,PVC的发生率最低,而PICC的发生率最高。有限的直接比较证据表明PVC与中心静脉导管(CVC)之间无统计学显著差异。
在标准化程序下,PVC可能是输注血管升压药的可行选择,尤其是MC,其外渗风险最低。由于存在血栓形成的潜在风险,使用PICC时应谨慎,而传统PVC应仅限于短期或紧急使用。未来需要设计良好且定义标准化的研究来加强证据的可靠性和临床适用性。